BRAND NAME:

Vascutril

GENERIC NAME:

Sacubitril + Valsartan

THERAPEUTIC SEGMENT:

Angiotensin Receptor – Neprilysin Inhibitor

INDICATIONS:

Vascutril is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Vascutril is indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Vascutril reduces NT-proBNP and is expected to improve cardiovascular outcomes.

BRIEF DESCRIPTION:

Sacubitril/Valsartan is an orally bioavailable combination of a neprilysin inhibitor (Sacubitril) and an angiotensin II receptor blocker (Valsartan) that works synergistically to enhance natriuretic peptide activity while suppressing the renin-angiotensin-aldosterone system (RAAS). Sacubitril inhibits neprilysin, preventing the degradation of natriuretic peptides, leading to vasodilation, natriuresis, and reduced cardiac remodeling. Valsartan selectively blocks the angiotensin II type 1 (AT₁) receptor, reducing vasoconstriction and aldosterone secretion. This dual mechanism reduces preload and afterload, improving cardiac efficiency, making Sacubitril/Valsartan a key therapy for heart failure with reduced ejection fraction (HFrEF).

DOSAGE FORM:

Tablets

24mg+26mg,

49mg + 51mg and

97mg + 103mg